GI Partners, a private equity investment firm, completed an investment in Clinical Ink, a global clinical trial technology company. Existing investor NovaQuest will continue as a minority investor in the company. Financial terms were not disclosed. "GI Partners’ acquisition is a powerful validation of our eSource vision for clinical trials and will add to our growing momentum in the marketplace. We are the undeniable leader in delivering eSource solutions across all phases and therapeutic areas. This transaction will help accelerate the adoption of our business model at a time when the weaknesses and frailties of the current clinical technology landscape are so starkly apparent. I’m excited to work with GI Partners as we launch our latest innovations later this year and expand into Asia-Pacific and Europe to support our customers’ global operations," Ed Seguine, Clinical Ink CEO.